Vimta Labs Limited — PPTs, 28-01-2026: Investor Presentation

Vimta Labs reported its financial results for the quarter and nine-month period ending FY26. Total Income for Q3 reached Rs 100.5 Cr, a modest 0.4% YoY increase, with PAT at Rs 17.6 Cr (up 0.4% YoY). For the nine months (9M FY26), total income saw robust growth of 20.7% YoY to Rs 304.3 Cr, and PAT increased 16.4% YoY to Rs 56.4 Cr. The company leads in Pharma Analytical and Food Testing in India, with significant overseas contributions from Clinical Research.

Growth is propelled by increasing demand for new drugs, biologics, and evolving food safety standards. Strategic priorities include capacity expansions, service innovations, new market entry, and cultivating strong customer partnerships. The company benefits from 'Make in India' initiatives for electronics and growing environmental awareness.

Vimta Labs continues to leverage its 41+ years of expertise and 600,000+ sq. ft. of advanced lab spaces across 10 locations, upholding a strong regulatory compliance record. Q3 FY26 EBITDA was Rs 34.4 Cr (34.3% margin), and 9M FY26 EBITDA reached Rs 106.8 Cr (35.1% margin). Basic EPS for 9M FY26 was Rs 12.7. The company maintains a healthy cash position of Rs 66.66 Cr with low debt of Rs 4.52 Cr. Management's outlook points to favorable market conditions, with plans for operational excellence, talent acquisition, cutting-edge technologies, and a strong quality culture.